PATH | VRL
Menu

Herd Immunity and Pneumococcal Conjugate Vaccine: A Quantitative Model

An empirical quantitative model was developed to estimate the herd (indirect) effects on the incidence of invasive disease among persons ≥5 years of age induced by vaccination of young children with 1, 2, or ≥3 doses of the pneumococcal conjugate vaccine, Prevnar (PCV7), containing serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. From 1994 to 2003, cases of invasive pneumococcal disease were prospectively identified in Georgia Health District-3 (eight metropolitan Atlanta counties) by Active bacterial core surveillance (ABCs). From 2000 to 2003, vaccine coverage levels of PCV7 for children aged 19 to 35 months in Fulton and DeKalb counties (of Atlanta) were estimated from the National Immunization Survey (NIS). Based on incidence data and the estimated average number of doses received by 15 months of age, a Poisson regression model was fit, describing the trend in invassive pneumococcal disease in groups not targeted for vaccination (i.e., adults and older children) before and after the introduction of PCV7. This article was published in the journal Vaccine.

Author: Haber M, Barskey A, Baughman W, et al.

Published: 2007

» Download file (English)

532 KB PDF (Located at www.sciencedirect.com)

Citation: Haber M, Barskey A, Baughman W, et al. Herd Immunity and Pneumococcal Conjugate Vaccine: A Quantitative Model. Vaccine. 2007;25(29):5390-5398.

Resource types: Peer-reviewed journal

Diseases/vaccines: Pneumococcus

Topics: Disease/vaccine specific information

Regions: Global